The 2013 guidelines from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology recommend EGFR mutation testing for adenocarcinomas and mixed lung cancers with an adenocarcinoma component regardless of clinical characteristics or risk factors 16. Here, EGFR is linked to lung cancer.